Form 4: CalciMedica Director Robert N. Wilson Acquires Stock Options
SEC Form 4 Filing
Director Robert N. Wilson reports acquisition of stock options in CalciMedica, Inc.
Summary
- Robert N. Wilson, a director of CalciMedica, Inc., reported a transaction involving derivative securities.
- On August 27, 2024, Wilson acquired stock options for 10,000 shares of common stock at an exercise price of $4.16.
- The options vest in equal monthly installments over one year, starting March 28, 2024, and expire on August 26, 2034.
- Following the transaction, Wilson directly owns derivative securities for 10,000 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing indicating a director's stock option acquisition.
Positives
- The acquisition of stock options by a director could signal confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of individuals with privileged information.
Stakeholder Impact
- The acquisition of stock options by a director can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| March 28, 2024 | Start date for monthly vesting of stock options. |
| August 27, 2024 | Date of stock option acquisition. |
| August 26, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.